Now, after years of fruitlessefforts to deal with taxanes' shortcomings, Bristol-Myers (nyse: BMY - news - people ) and rival Aventis (nyse: AVE - news - people ) (which produces another taxane called docetaxal, under the name Taxotere) each have promising new variations.